Buyback yield (TTM)
0.64%
Shareholder yield (TTM)
1.32%
5Y share count change
-6.1%
Buyback spend (TTM)
$5.26B
Cumulative buybacks
$32.77B
Key takeaways
- Eli Lilly (LLY) repurchased about $5.26B of stock over the trailing twelve months.
- Diluted share count is down 6.1% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 8.31× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +52.4% per year over the latest 5-year window.
- TTM repurchases used about 66% of free cash flow remaining after dividends.
Dividend & buyback yield over time for Eli Lilly (LLY)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Eli Lilly (LLY)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Eli Lilly (LLY)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Eli Lilly (LLY)
Latest: $4.11B
Overview
In 2025, Eli Lilly (LLY) buyback spend totalled $4.11B – surged 64.3% year-over-year.
Across 2020–2025 (5 years), Eli Lilly buyback spend produced a CAGR of +52.4% – sustaining 2 straight years of year-over-year growth.
Eli Lilly buyback spend peaked at $4.40B in 2019; the latest annual figure is $4.11B in 2025 (6.6% below peak).
Across the available history, buyback spend reached its high of $4.40B in 2019 and its low of $0.00 in 2004.
Eli Lilly Buyback Spend 2025: $4.11B
In 2025, Eli Lilly reported buyback spend of $4.11B, surged 64.3% from 2024.
Eli Lilly Buyback Spend 2024: $2.50B
Eli Lilly buyback spend in 2024 was $2.50B, surged 233.3% from 2023.
Eli Lilly Buyback Spend 2023: $750.00M
2023's buyback spend for Eli Lilly came in at $750.00M, plunged 50.0% below 2022.
Eli Lilly Buyback Spend 2022: $1.50B
Eli Lilly posted buyback spend of $1.50B in 2022, grew 20.0% from 2021.
Eli Lilly Buyback Spend 2021: $1.25B
Eli Lilly buyback spend in 2021 was $1.25B.
See more financial history for Eli Lilly (LLY).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $4.11B | $626.00M | $3.48B | 0.43% | 0.90B | -0.7% | |
| 2024 | $2.50B | $645.60M | $1.85B | 0.36% | 0.90B | +0.1% | |
| 2023 | $750.00M | $628.50M | $121.50M | 0.14% | 0.90B | -4.9% | |
| 2022 | $1.50B | $371.10M | $1.13B | 0.43% | 0.95B | -0.4% | |
| 2021 | $1.25B | $342.80M | $907.20M | 0.47% | 0.95B | -0.3% | |
| 2020 | $500.00M | $308.10M | $191.90M | 0.31% | 0.96B | -0.1% | |
| 2019 | $4.40B | $312.40M | $4.09B | 3.50% | 0.96B | -7.4% | |
| 2018 | $4.15B | $279.50M | $3.87B | 3.49% | 1.03B | -1.7% | |
| 2017 | $299.80M | $281.30M | $18.50M | 0.34% | 1.05B | -4.4% | |
| 2016 | $600.10M | $255.30M | $344.80M | 0.74% | 1.10B | -0.4% | |
| 2015 | $749.50M | $217.80M | $531.70M | 0.80% | 1.11B | -0.5% | |
| 2014 | $800.00M | $156.00M | $644.00M | 1.04% | 1.11B | -0.6% | |
| 2013 | $1.70B | $144.90M | $1.55B | 2.98% | 1.12B | -2.6% | |
| 2012 | $721.10M | $141.50M | $579.60M | 1.28% | 1.15B | +2.9% | |
| 2011 | $0.00 | $147.40M | −$147.40M | — | 1.11B | +0.7% | |
| 2010 | $0.00 | $231.00M | −$231.00M | — | 1.11B | +0.7% | |
| 2009 | $0.00 | $368.50M | −$368.50M | — | 1.10B | +0.4% | |
| 2008 | $0.00 | $255.30M | −$255.30M | — | 1.09B | +0.3% | |
| 2007 | $0.00 | $0.00 | $0.00 | — | 1.09B | +0.4% | |
| 2006 | $122.10M | $0.00 | $122.10M | 0.22% | 1.09B | -0.6% | |
| 2005 | $377.90M | $0.00 | $377.90M | 0.61% | 1.09B | +0.3% | |
| 2004 | $0.00 | $0.00 | $0.00 | — | 1.09B | +0.9% | |
| 2003 | $281.10M | $0.00 | $281.10M | 0.37% | 1.08B | -0.2% | |
| 2002 | $385.20M | $0.00 | $385.20M | 0.56% | 1.08B | -0.6% | |
| 2001 | $545.70M | $0.00 | $545.70M | 0.65% | 1.09B | -0.5% | |
| 2000 | $1.05B | $0.00 | $1.05B | — | 1.10B | -0.9% | |
| 1999 | $1.45B | $0.00 | $1.45B | — | 1.11B | -1.3% | |
| 1998 | $2.17B | $0.00 | $2.17B | — | 1.12B | -0.9% | |
| 1997 | $351.30M | $0.00 | $351.30M | — | 1.13B | +1.2% | |
| 1996 | $314.50M | $0.00 | $314.50M | — | 1.12B | — | |
| 1995 | $156.00M | $0.00 | $156.00M | — | — | — | |
| 1994 | $111.00M | $0.00 | $111.00M | — | — | — | |
| 1993 | $25.80M | $0.00 | $25.80M | — | — | — | |
| 1992 | $68.50M | $0.00 | $68.50M | — | — | — | |
| 1991 | $69.20M | $0.00 | $69.20M | — | — | — | |
| 1990 | $1.07B | $0.00 | $1.07B | — | — | — | |
| 1989 | $186.90M | $0.00 | $186.90M | — | — | — |
- 2025$4.11B
- 2024$2.50B
- 2023$750.00M
- 2022$1.50B
- 2021$1.25B
- 2020$500.00M
- 2019$4.40B
- 2018$4.15B
- 2017$299.80M
- 2016$600.10M
- 2015$749.50M
- 2014$800.00M
- 2013$1.70B
- 2012$721.10M
- 2011$0.00
- 2010$0.00
- 2009$0.00
- 2008$0.00
- 2007$0.00
- 2006$122.10M
- 2005$377.90M
- 2004$0.00
- 2003$281.10M
- 2002$385.20M
- 2001$545.70M
- 2000$1.05B
- 1999$1.45B
- 1998$2.17B
- 1997$351.30M
- 1996$314.50M
- 1995$156.00M
- 1994$111.00M
- 1993$25.80M
- 1992$68.50M
- 1991$69.20M
- 1990$1.07B
- 1989$186.90M
Buybacks vs stock-based compensation for Eli Lilly (LLY)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 8.31×.
Buybacks vs dividends (share of cash returned) for Eli Lilly (LLY)
How Eli Lilly splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Eli Lilly, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $3.00B | |
| $980.00M | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $980.00M
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $7.99B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation